M. Lucas

发表

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.

Thomas S. Lin, J. Byrd, I. Flinn, 2005, Blood.

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

M. Grever, J. Byrd, I. Flinn, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.

M. Grever, J. Byrd, K. Blum, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Lisa L. Smith, M. Grever, J. Byrd, 2004, Blood.

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.

Jeffrey A Jones, J. Byrd, N. Heerema, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

J. Byrd, F. Awan, A. Johnson, 2010, Leukemia & lymphoma.

Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia

J. Byrd, L. Naumovski, P. Lecane, 2009, Leukemia & lymphoma.

with p53 mutations and deletions Alemtuzumab is an effective therapy for chronic lymphocytic leukemia

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

Antibody therapy for chronic lymphocytic leukemia: a promising new modality.

M. Grever, J. Byrd, D. Fischer, 2004, Hematology/oncology clinics of North America.

Rituximab in B-cell chronic lymphocytic leukemia.

J. Byrd, M. Lucas, T. Lin, 2003, Seminars in oncology.

to alemtuzumab in chronic lymphocytic leukemia FCGR3A and FCGR2A polymorphisms may not correlate with response

J. Byrd, I. Flinn, R. Modali, 2013 .

FCGR3A and FCGR2A Polymorphisms May Not Correlate with Response to Alemtuzumab (Campath-1H) in Chronic Lymphocytic Leukemia (CLL)

J. Byrd, I. Flinn, R. Modali, 2013 .

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.

Jeffrey A Jones, J. Byrd, N. Heerema, 2018, Blood.

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia

M. Grever, J. Byrd, I. Flinn, 2005, Leukemia.

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

M. Grever, J. Byrd, I. Flinn, 2009, Leukemia & lymphoma.

Chronic lymphocytic leukemia.

J. Byrd, T. Hamblin, G. Dewald, 2010, Hematology. American Society of Hematology. Education Program.

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma

Jeffrey A Jones, J. Byrd, F. Awan, 2015, Leukemia & lymphoma.

Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia

J. Byrd, M. Lucas, T. Lin, 2004 .

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia

J. Byrd, E. Kimby, D. Agus, 2001, Journal of immunotherapy.

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.

J. Byrd, R. Larson, K. Rai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.

J. Byrd, E. Kimby, D. Agus, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.

Jeffrey A Jones, J. Byrd, F. Awan, 2020, Blood advances.

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

M. Caligiuri, J. Byrd, N. Heerema, 2009, Leukemia.

BTK C 481 S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

M. Grever, J. Byrd, F. Awan, 2017 .

Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia

S. Goodman, M. Grever, J. Byrd, 2005, Clinical Cancer Research.

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2016 .

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

M. Grever, J. Byrd, E. Kraut, 2004 .

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

M. Grever, J. Byrd, K. Blum, 2004 .

Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.

J. Byrd, J. Rosenberg, W. Velasquez, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

J. Byrd, R. Larson, B. Peterson, 2007 .

Antibody therapy of acute and chronic leukemias.

J. Byrd, S. Cataland, M. Lucas, 2001, Current Pharmaceutical Biotechnology.

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

M. Caligiuri, M. Grever, J. Byrd, 2006 .

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.

Jeffrey A Jones, N. Heerema, F. Awan, 2018, Blood.